Why the study?
Does the introduction of a high-sensitivity troponin assay improve the detection of myocardial infarction and alter clinical management in patients presenting to the ED?
Does the introduction of a high-sensitivity troponin assay improve the detection of myocardial infarction and alter clinical management in patients presenting to the ED?
The introduction of a high-sensitivity troponin assay in the ED increased hospital admissions without improving the detection of acute myocardial infarction or changing revascularization rates.
Answers are grounded in this paper and cite their sources.
Hs-Tn introduction raised abnormal troponin rates while shortening ED stays; leaves open net effect on unnecessary testing or admissions.
OBJECTIVE: Biomarkers are a critical component in the investigation of patients with potential ischaemic heart disease. The proposed benefits of a high-sensitivity troponin (hs-Tn) assay include earlier diagnosis of myocardial infarction. However, the decreased specificity may adversely affect clinical practice. The present study aims to investigate the impact that the introduction of a hs-Tn assay had on patients presenting to the ED. METHODS: A pre- and post-interventional analysis was performed on all patients presenting to the Royal Melbourne Hospital ED, and had a troponin, in the 12 months before and after the introduction of the hs-Tn assay. The main outcome measures were ED length of stay, admission rates, proportion of patients undergoing interventional cardiac procedures and proportion diagnosed with myocardial infarction. RESULTS: There were 6557 patients who had a conventional assay and 7335 patients who had a hs-Tn assay. The introduction of a hs-Tn assay was associated with an increased abnormal troponin rate (23.4% vs 28.1%, P < 0.001). The median length of ED stay decreased by 9.1% (P < 0.001). The proportion admitted to hospital increased (60.9% vs 65.9%, P < 0.001); however, there was no difference in the proportion undergoing revascularisation or the proportion diagnosed with myocardial infarction. CONCLUSIONS: Although the introduction of a hs-Tn assay led to an increase in hospital admissions, the unchanged rate of cardiac procedures or final diagnoses of acute myocardial infarction and ischaemic heart disease suggests that the hs-Tn did not improve the detection of these conditions. It remains unclear whether there was a benefit admitting the additional cohort of patients.
No takes yet. Share an insight, caveat, or question.
Peck et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: